Progresses in the treatment of exudative age-related macular degeneration with anti-vascular endothelial growth factor drugs
10.3760/cma.j.issn.1005-1015.2018.05.021
- VernacularTitle:渗出型老年性黄斑变性治疗中抗血管内皮生长因子药物治疗中更换应用的研究进展
- Author:
Xueli DU
1
;
Wenbo LI
;
Bojie HU
Author Information
1. 300384,天津医科大学眼科医院天津医科大学眼科研究所天津医科大学眼视光学院
- Keywords:
Wet macular degeneration/drug therapy;
Angiogenesis inhibitors/therapeutic use;
Antibodies,monoclonal,humanized/therapeutic use;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2018;34(5):498-503
- CountryChina
- Language:Chinese
-
Abstract:
Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs,including monoclonal antibodies (such as bevacizumab and ranibizumab) and fusion protein agents (such as aflibercept and conbercept) have been proven to be effective in the treatment of wet age-related macular degeneration (wAMD).However,there are still some patients with poor efficacy,such as no response to initial treatment or poor response,and even relapse during the course of treatment.In view of the different targets and molecular characteristics of anti-VEGF drugs,the switch of anti-VEGF drugs and the adjustment of delivery pattern,dosages and intervals have been the strategies to cope with the poor efficacy in clinic.However,there are some differences in the results of current studies.Overall,the recovery of retinal anatomical outcome achieves more benefits,and it is relatively difficult to improve visual acuity.To determine which regimen would get the biggest benefits,a large number of randomized controlled clinical trials and long study period will be needed.
